Contribution of mdr1b-type P-glycoprotein to okadaic acid resistance in rat pituitary GH3 cells.
Okadaic acid as well as other, structurally different, inhibitors of serine/threonine phosphatases 1 and 2A induce apoptosis in pituitary GH3 cells. Incubation with stepwise raised concentrations of okadaic acid resulted in the isolation of cells that were increasingly less sensitive to the cytotoxic effect of this agent. After about 18 months cells were selected that survived at 300 nM okadaic acid, which is about 30 times the initially lethal concentration. This study revealed that a major pharmacokinetic mechanism underlying cell survival was the development of a P-glycoprotein-mediated multidrug resistance (MDR) phenotype. The increase in mRNA levels of the mdr1b P-glycoprotein isoform correlated with the extent of drug resistance. Functional assays revealed that increasing drug resistance was paralleled by a decreased accumulation of rhodamine 123, a fluorescent dye which is a substrate of mdr1-mediated efflux activity. Resistance could be abolished by structurally different chemosensitizers of P-glycoprotein function like verapamil and reserpine but not by the leukotriene receptor antagonist MK571 which is a modulator of the multidrug resistance-associated protein (MRP). Okadaic acid resistance included cross-resistance to other cytotoxic agents that are substrates of mdr1-type P-glycoproteins, like doxorubicin and actinomycin D, but not to non-substrates of mdr1, e.g. cytosine arabinoside. Thus, functional as well as biochemical features support the conclusion that okadaic acid is a substrate of the mdr1-mediated efflux activity in rat pituitary GH3 cells. Maintenance of resistance after withdrawal of okadaic acid as well as metaphase spreads of 100 nM okadaic acid-resistant cells suggested a stable MDR genotype without indications for the occurrence of extrachromosomal amplifications, e.g. double minute chromosomes.
Ritz
V
V
Institute of Pharmacology and Toxicology, University of Göttingen, Germany.
Marwitz
J
J
Sieder
S
S
Ziemann
C
C
Hirsch-Ernst
K I
KI
Quentin
I
I
Steinfelder
H J
HJ
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000145:classification / Q000235:genetics / Q000502:physiology*; D000818:Animals; D015152:Blotting, Northern; D015153:Blotting, Western; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance / Q000502:physiology*; D004791:Enzyme Inhibitors / Q000633:toxicity*; D008677:Metaphase / Q000187:drug effects*; D019319:Okadaic Acid / Q000633:toxicity*; D010902:Pituitary Gland / Q000502:physiology*; D020033:Protein Isoforms; D051381:Rats; D020112:Rhodamine 123 / Q000378:metabolism; D013997:Time Factors
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D004791:Enzyme Inhibitors; D020033:Protein Isoforms; D020112:Rhodamine 123; D019319:Okadaic Acid